WO2007082698A1 - Composition moussante - Google Patents

Composition moussante Download PDF

Info

Publication number
WO2007082698A1
WO2007082698A1 PCT/EP2007/000271 EP2007000271W WO2007082698A1 WO 2007082698 A1 WO2007082698 A1 WO 2007082698A1 EP 2007000271 W EP2007000271 W EP 2007000271W WO 2007082698 A1 WO2007082698 A1 WO 2007082698A1
Authority
WO
WIPO (PCT)
Prior art keywords
foam
composition
mpa
composition according
forming composition
Prior art date
Application number
PCT/EP2007/000271
Other languages
English (en)
Inventor
Francois Jean-Louis Jerome Boutignon
Jean-Marc Aiache
Thomas Jean Henri Barres
Florian Tapissier
Original Assignee
Disphar International B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06100572A external-priority patent/EP1810666A1/fr
Application filed by Disphar International B.V. filed Critical Disphar International B.V.
Priority to JP2008550673A priority Critical patent/JP5184373B2/ja
Priority to AU2007207116A priority patent/AU2007207116B2/en
Priority to US12/161,102 priority patent/US8206688B2/en
Priority to EP07702743A priority patent/EP1981480A1/fr
Priority to CA2637408A priority patent/CA2637408C/fr
Priority to BRPI0706650-3A priority patent/BRPI0706650A2/pt
Publication of WO2007082698A1 publication Critical patent/WO2007082698A1/fr
Priority to NO20083524A priority patent/NO20083524L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • the present invention relates to a novel foam-forming composition suitable for rectal administration of prednisolone and a product adapted to administer said foam-forming composition. Also, the present invention relates to a method for its preparation.
  • BACKGROUND OF THE INVENTION Left-sided (distal) ulcerative colitis and ulcerative proctitis are disease subtypes of ulcerative colitis with multiple treatment options.
  • topical rectal therapies with aminosalicylates or glucocorticoid formulations [R. D. Cohen et al. The American Journal of Gastroenterology; Vol.95, No. 5, 2000: p. 1263].
  • Suitable dosage forms for rectal delivery include suppositories, foams and liquid enemas, which differ with respect to their physiochemical properties and potential for proximal spread.
  • the efficacy of the therapy is dependent upon direct contact of this active ingredient with the inflamed mucosa. Hence it is important that a highly expanded volume of the foam is obtained in order to provide wide distribution throughout the diseased area.
  • Such delayed foaming may be achieved by providing a composition in a pressurised container wherein the propellant is physically separated from said composition.
  • the disadvantage of this single-dosage foaming composition is that although a highly expanded volume of the foam of up to 275 ml may be obtained, the initial volume of the unfoamed composition to be dosed is also extremely high (22 ml).
  • Such high initial volume is disadvantageous since it requires the use of a large canister, especially when multiple doses are to be contained in said canister.
  • the packaging and distribution of large canisters is an economic disadvantage. Furthermore, such large canister is very impractical to handle for the patient.
  • aerosol foams are complicated physical- chemical structures that do not form under arbitrary circumstances.
  • a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam or alternatively the foam is not formed at all, especially when administration is to occur via an applicator nozzle with small diameter.
  • a given formulation may not simply be adapted without further provisions to result in the desired foam.
  • the problem with highly expandable foam-forming compositions according to the prior art is that due to their appearance preliminary ejection of said formed foam is easily induced. This results in insufficient retention of the active ingredient to the mucosa of the inflamed area which is necessary to obtain optimal results in combating the disease.
  • the present invention provides a foam-forming composition which exhibits a highly expanded foam volume and at the same time confers an appearance that allows sufficient contact time of the active to the target site in the intestine such as to obtain optimal local effect of the pharmaceutical active ingredient present in the foam.
  • an aqueous foam-forming composition suitable for rectal administration of a therapeutically effective amount of prednisolone or its pharmaceutically acceptable derivatives, characterized in that said composition has a volume expansion ratio in the range of 26 to 70.
  • the volume expansion ration is at least 26, preferably at least 28, more preferably at least 30.
  • the volume expansion ratio is less than 70, more preferably less than 60, most preferably less than 50.
  • the initial volume V may be determined from the weight of the emitted dose divided by its density at 37°C (generally, for aqueous compositions, the density is 1).
  • a foam-forming composition with increased volume expansion ratio a foam is generated with an advantageous appearance, i.e. it collapses rather quickly but a thin layer of the components of the foam including the prednisolone remains on the surface of the intestine.
  • This advantageous appearance allows for sufficient contact time between the active pharmaceutical ingredient and the mucous of the inflamed area, whereas a preliminary ejection reflex is at the same time minimised.
  • Optimal uptake of the prednisolone from the foam into the inflamed mucous is hence established.
  • the composition of the present invention is an aqueous composition.
  • an aqueous composition means that a majority of the weight volume of the composition is composed of water, also referred to as the aqueous carrier.
  • the composition of the present invention comprises 57-97 weight percent of water, more preferably 65-95 weight percent.
  • This aqueous carrier obviously also covers any aqueous buffer solution such as for example a phosphate buffer which apart from water also contain potassium phosphate and amounts of sodium hydroxide and hydrochloric acid to obtain the desired pH.
  • said aqueous composition does not include emulsifying waxes and/or mineral oils.
  • the disadvantage of these components is that they might further irritate the already inflamed areas of the intestine.
  • the composition of the present invention comprises at least one surfactant, a thickening agent and a propellant.
  • a person skilled in the art may first check the compatibility of said ingredients with the active ingredient.
  • the thickening agent in the composition of the present invention may be chosen from any water-soluble polymer.
  • said thickening agent is a water-soluble cellulose polymer.
  • the following polymers may be included in the composition, e.g.
  • the weight percent of thickening agent is between 0.01 to 1 % (w/w). In the present invention the amount is at most 1.0%, preferably at most 0.5%, more preferably it is at most 0.3% (w/w) of the composition. In the present invention, the minimum amount is at least 0.01%, preferably at least 0.05%, more preferably at least 0.1% (w/w) of the composition.
  • the precise identity of the surfactant present in the composition of the present invention is not critical and may be chosen from those which have an effective emulsifying action in combination with water and the foaming agent.
  • a mixture of two or more different surfactants is used.
  • at least one surfactant may provide the emulsifying action, whereas the other may provide a foam-stabilizing action.
  • Known anionic and non-ionic surfactants may be used.
  • the surfactant may be a mixture of at least two non-ionic surfactants since these are less irritating.
  • Non-ionic surfactants may include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate, sorbitan esters such as sorbitan monostearate, caprylocaproyl macrogolglycerides such as Labrasol®.
  • glycerol fatty acid esters such as glycerol monostearate
  • glycol fatty acid esters such as propylene glycol monostearate
  • polyhydric alcohol fatty acid esters such as polyethylene glycol monooleate
  • polyoxyethylene fatty acid esters such as polyoxyethylene stearate
  • non- ionic surfactants that increase the viscosity of the foam-forming composition should be avoided.
  • a mixture of caprylocaproyl macrogolglycerides and polyoxyethylene 80 sorbitan monooleate is used.
  • the total amount of surfactant present in the composition makes up from 1% to 15% (w/w) of the composition, preferably it makes up less than 10% (w/w) of the total weight of the composition.
  • the composition contains a lubricant.
  • said lubricant is silicone.
  • silicone further stabilizes the foam-forming composition. More preferably the silicone is polydimethylsiloxane.
  • the amount of lubricant is at least 0.1 %, preferably at least 0.5 %, more preferably at least 1% (w/w) of the composition and at most 10%, preferably at most 5%, more preferably at most 3% (w/w) of the composition.
  • the propellant according to the present invention is used to accomplish the foaming effect.
  • the propellant may be chosen according to known principles for preparing a foamable composition of the aerosol type packed in a pressurized container and suitable for a rectal application.
  • the propellant may be any suitable gas such as a low molecular weight hydrocarbon e.g. isobutane, N-butane, propane, pentane, CFC, HFC, or air.
  • the propellant comprises a mixture of butane, isobutane, propane (B. I. P.).
  • the propellant may have a vapour pressure within the range of 0.5 to 2.5 bars (at ambient temperature).
  • the propellant may be present in an amount from 4 to 12% (w/w) of the composition.
  • said amount is between 6 to 10%, more preferably between 7 to 9% (w/w) of the composition.
  • liquefied nitrogen may be present as pressurising agent to obtain the required number of doses.
  • the pressure in a multi-dosage container is in the range of 5 to 12, more preferably 7 to 11 bars, and even more preferably 6 to 8 bars.
  • composition of the present invention is suitable for rectal administration of a therapeutically effective amount of prednisolone or its pharmaceutically acceptable derivative.
  • the pharmaceutically acceptable derivative of prednisolone may be locally-acting forms of prednisolone.
  • it is prednisolone metasulphobenzoate.
  • the pharmaceutically acceptable salt is preferably a sodium salt.
  • other locally-acting pharmaceutically active ingredients may be used.
  • they are selected from the group consisting of tixocortol pivalate, fluticasone propionate, beclomethasone dipropionate, mesalazine, budesonide and pharmaceutically acceptable salts of any of these.
  • the pharmaceutically active ingredient may be present in any effective amount that causes a therapeutically effect in the patient.
  • the pharmaceutically active ingredient is preferably present in amounts of approximately 0.005% by weight to approximately 10% by weight, more preferably approximately 0.05% to approximately 2% by weight, based on the total weight of the foam-forming composition.
  • the foam-forming composition may also contain other ingredients such as preservatives, lubricants and chelating agents. Typical preservatives include sodium benzoate, sorbic acid, phenylethylic alcohol and parahydroxybenzoate.
  • the chelating agent may include EDTA.
  • a multi-dose pressurized aerosol container that comprises the foam-forming composition according to the invention.
  • the problem with foam-forming compositions comprised in a multi-dose aerosol container is the insufficient dose-repeatability of the emitted foam. It appears that the amount of active present in a single dose and the expansion volume of an emitted dose may fluctuate between the first and last dose in a range that is outside the target range. Since it is prerequisite for the development of an advantageous multi-dose rectal formulation that all given doses are within the specified narrow range with regard to both the amount of the active and the reached end-volume of the dose, such high dose- repeatability is critical for developing a commercially advantageous product.
  • the composition of the present invention preferably has a viscosity in the range of 2.0 to 20.0 mPa.s.
  • the viscosity of the composition is at least 2.0 mPa.s, preferably it is at least 4.0 mPa.s, more preferable at least 6.0 mPa.s and most preferable at least 7.0 mPa.s.
  • the viscosity of said composition is maximal 20.0 mPa.s, preferably it is less than 16.0 mPa.s, more preferably less than 12.0 mPa.s and most preferably less than 9.0 mPa.s.
  • viscosity of the foam-forming composition is meant the viscosity of the unfoamed composition comprising all components making up the foam-forming composition except the foaming agent(s).
  • the viscosity of the emulsion can be determined using any suitable viscosimeter operated according to standard procedures.
  • viscosities were measured by means of a Brookfield RVT with a cone plate CP 42 mobile for which the rotation speed of the emulsion during measurement is corrected with a standard coefficient.
  • the viscosity (in cP or mPa.s) is determined at 25°C and 100 rpm.
  • the multi-dose container comprises a metering valve.
  • Metering valves are valves that dispense a predetermined and constant dose of foam.
  • a metering valve adapted to dispense volumes of from approximately 1 to 5 cm 3 may be used (provided by Lablabo, France).
  • the container may be a coated aluminium canister. Further, the container can be fitted or supplied together with an application device for insertion into the rectum to ensure more efficient administration of the foam.
  • a method for preparation of the foam- forming composition is provided.
  • the foam-forming composition according to the present invention is prepared according to a method comprising the steps of admixing an aqueous carrier, a lubricant, a thickening agent, at least one surfactant and the pharmaceutically active ingredient to form a homogenous bulk emulsion.
  • said method comprises the steps of a) Admixing an aqueous carrier, a lubricant, at least one surfactant and a locally-acting pharmaceutically active ingredient or its pharmaceutically acceptable derivative to obtain a homogenous emulsion having a viscosity in the range of 2 to 20 mPa.s; and b) Adding to the emulsion obtained in step a) at least one propellant to form a foam-forming composition.
  • the preservatives and chelating agents are first admixed with the aqueous carrier by means of a homogenizer. Then, the thickening agent is admixed in the same way. Subsequently, the surfactant(s) and lubricant are admixed and the mixture may be solubilized and/or heated before the active ingredient is added. Alternatively, the active ingredient is admixed at the start.
  • Canisters may be filled with the bulk emulsion and subsequently after sealing, a propellant is added to form the foam-forming composition.
  • the foam-forming composition according to the present invention will usually be packed in a suitable pressurized dispensing canister of the aerosol type well known in the art such as an aluminium canister. Each canister is sealed with a suitable foam dispensing valve. Any valve or nozzle/valve assembly which provides a means for releasing the foam- forming emulsion from the container and provides a foam is suitable for use in the present invention.
  • the foam that is formed from the composition of the present invention has superior properties. The advantages associated with the highly expanded foam according to the present invention is that better results are obtained in combating the disease and either a lower dosage of the active ingredient or less dosages per day are necessary to obtain similar results when compared with prior art compositions.
  • the likelihood of inducing a defecation or rejection reflex on administration of said foam is lower than normally may be expected from foam having a high expansion volume.
  • the increased spreading of the foam together with the longer exposure time to the active will result in optimal local effect at the target site.
  • the foam of the present invention does not cause extra irritation of the inflamed target mucosa due to the absence of emulsifying waxes and/or technical oils as present in the prior art compositions. Due to these superior properties of the foam, the current invention represents a valuable alternative to previously known medicines used for the treatment of rectal diseases.
  • a pharmaceutical foam-forming composition was formulated with prednisolone sodium metasulphobenzoate as active ingredient according to the formula shown in Table I.
  • the bulk emulsion is prepared by introducing the Sorbic acid (E200), Phenylethyl alcohol (CAS 60-12-8) and Edetic acid (CAS 6381-92-6) into the water carrier while mixing in a Chabaud® mixer during 10 minutes at 1500 rpm. Subsequently the hydroxypropyl methylcellulose was added under quick stirring at 3000 rpm during 10 minutes, and further stirring for 60 minutes at 1000 rpm.
  • the polysorbate 80 (Montanox®, Seppic S.A.), the caprylocaproyl macrogolglycerides (Labrasol®, Gattefosse Corporation) and polydimethylsiloxane (Dow Corning® Q7-9120 silicone fluid, 100 CST, 425G, Dow Corning) was added under stirring for 15 minutes at 1500 rpm.
  • Prednisolone metasulphobenzoate sodium salt (CAS 630-67-1) was incorporated into the emulsion under quick stirring at 3000 rpm during 15 minutes.
  • the formed homogenous emulsion has a pH of 4.15. Viscosity was measured using a Brookfield viscometer (RTV mobile with Cone and plate CP 42).
  • This viscometer is a torque meter which is driven at discrete rotational speeds. The amount of torque that is indicated must be converted to absolute centipoise units (cP) or mPa-s from pre-calculated range charts (Brookfield). The viscosity measured at 25°C and 100 rpm was 7.6 mPa.s.
  • a monoblock canister (110 ml) was filled with 90 gram of the bulk emulsion according to experiment 1 , and further filled with the propellants B. I. P. (Novospray nbu/p25 of Avantec- dehon; 8.1 10 g) and as pressurizing agent Nitrogen (0.09 g) is added using a pressurisation unit and resulting in a pressure of 12 bars.
  • the canister was closed with a 3 ml metering valve (Lablabo S.A.).
  • the canister contains material for 14 dosages (and 20% overdoses) and the repeatability of the dose and the expansion volume was established by measuring respectively the volumic mass (g/ml) and the expansions volume (ml) of the 1 st and the 14 th dose (Table II).
  • Expansion volume was determined by emitting a single dose (3 ml) into the down extremity of a plastic tube that stand in a vertical position having an internal diameter (I. D) of 1.2 cm and a length of 100 cm and having a scale indication in centimetres.
  • the volume expansion ratio was found to be 30.
  • the volumic mass (g/ml) of a single dose is calculated by dividing the weight of the dose (g) by the expansion volume (ml).
  • the weight of the dose is determined by measuring on a balance (Mettler PR 802, 0.01 mg precision) the difference in weight of the canister before and after emitting said dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle composition moussante conçue pour l’administration par voie rectale d’agents pharmaceutiquement actifs à action locale. L’invention concerne également le produit destiné à administrer la composition moussante ainsi qu’un procédé pour la préparer. La composition moussante selon l’invention fait preuve d’un taux d’expansion élevé et confère en même temps un aspect optimal à la mousse formée permettant à l’agent actif d’être en contact avec le site cible dans l’intestin pendant une durée suffisante pour obtenir un effet local optimal. Ladite composition offre des qualités supérieures pour le traitement de maladies affectant le rectum.
PCT/EP2007/000271 2006-01-19 2007-01-12 Composition moussante WO2007082698A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008550673A JP5184373B2 (ja) 2006-01-19 2007-01-12 発泡組成物
AU2007207116A AU2007207116B2 (en) 2006-01-19 2007-01-12 Foam-forming composition
US12/161,102 US8206688B2 (en) 2006-01-19 2007-01-12 Foam-forming composition
EP07702743A EP1981480A1 (fr) 2006-01-19 2007-01-12 Composition moussante
CA2637408A CA2637408C (fr) 2006-01-19 2007-01-12 Composition moussante
BRPI0706650-3A BRPI0706650A2 (pt) 2006-01-19 2007-01-12 composição de formação de espuma
NO20083524A NO20083524L (no) 2006-01-19 2008-08-13 Skumdannende preparat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06100572.4 2006-01-19
EP06100572A EP1810666A1 (fr) 2006-01-19 2006-01-19 Composition de mousse
US76177906P 2006-01-25 2006-01-25
US60/761,779 2006-01-25

Publications (1)

Publication Number Publication Date
WO2007082698A1 true WO2007082698A1 (fr) 2007-07-26

Family

ID=37831688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/000271 WO2007082698A1 (fr) 2006-01-19 2007-01-12 Composition moussante

Country Status (6)

Country Link
EP (1) EP1981480A1 (fr)
JP (1) JP5184373B2 (fr)
AU (1) AU2007207116B2 (fr)
CA (1) CA2637408C (fr)
NO (1) NO20083524L (fr)
WO (1) WO2007082698A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150530A2 (fr) * 2008-06-11 2009-12-17 Ferring International Center Sa Nouvelle composition de mousse
EP2268136A2 (fr) * 2008-03-19 2011-01-05 Waterbury Companies, Inc. Composition de mousse pour canalisations et ses procédés d'utilisation
US20120213709A1 (en) * 2009-07-29 2012-08-23 Foamix Ltd. Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015168654A (ja) * 2014-03-07 2015-09-28 三笠製薬株式会社 ＮＳＡＩＤｓ含有泡沫化製剤用水性組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725872A (en) * 1993-12-14 1998-03-10 Ferring Bv Composition for foams, notably rectal foams, and foams thus obtained
US5972310A (en) * 1994-07-21 1999-10-26 Tillotts Pharma Ag Aqueous foamable composition
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof
US20050271598A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Body cavity foams

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9000485D0 (sv) * 1990-02-09 1990-02-09 Pharmacia Ab Foamable composition for pharmaceutical use, use thereof and method of treatment
IT1243379B (it) * 1990-07-27 1994-06-10 Giuliani Spa Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico
SE9703226D0 (sv) * 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725872A (en) * 1993-12-14 1998-03-10 Ferring Bv Composition for foams, notably rectal foams, and foams thus obtained
US5972310A (en) * 1994-07-21 1999-10-26 Tillotts Pharma Ag Aqueous foamable composition
US20050271598A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Body cavity foams
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
EP2268136A4 (fr) * 2008-03-19 2011-11-23 Waterbury Co Inc Composition de mousse pour canalisations et ses procédés d'utilisation
EP2268136A2 (fr) * 2008-03-19 2011-01-05 Waterbury Companies, Inc. Composition de mousse pour canalisations et ses procédés d'utilisation
WO2009150530A2 (fr) * 2008-06-11 2009-12-17 Ferring International Center Sa Nouvelle composition de mousse
WO2009150530A3 (fr) * 2008-06-11 2010-10-28 Ferring International Center Sa Nouvelle composition de mousse
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9167813B2 (en) * 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) * 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US20120213709A1 (en) * 2009-07-29 2012-08-23 Foamix Ltd. Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
EP1981480A1 (fr) 2008-10-22
NO20083524L (no) 2008-08-13
JP5184373B2 (ja) 2013-04-17
AU2007207116A1 (en) 2007-07-26
AU2007207116B2 (en) 2012-08-02
CA2637408C (fr) 2013-12-03
CA2637408A1 (fr) 2007-07-26
JP2009523745A (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
CA2637408C (fr) Composition moussante
AU759515B2 (en) Topical sprays comprising a film forming composition
US6962691B1 (en) Topical spray compositions
AU731208B2 (en) New foam-forming pharmaceutical composition
AU701373B2 (en) Aqueous foamable composition
EP0395329B1 (fr) composition sous forme de mousse contenant l'acide amino-5 salicylique pour administration intra-rectale
WO2006010589A2 (fr) Mousse en gel post-moussant
EP2964196A1 (fr) Compositions pharmaceutiques pour administration rectale
US8206688B2 (en) Foam-forming composition
JP2022163191A (ja) 直腸フォーム製剤
MX2008009090A (es) Composicion formadora de espuma
WO2009150530A2 (fr) Nouvelle composition de mousse
JPH05124955A (ja) 噴霧用ゲル基剤およびそれを用いた噴霧用点鼻剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009090

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007207116

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2637408

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008550673

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200780002784.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3025/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 570177

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007702743

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007207116

Country of ref document: AU

Date of ref document: 20070112

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2007207116

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12161102

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0706650

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080721